These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 8894350)
1. Carrier effects on biological activity of amphotericin B. Brajtburg J; Bolard J Clin Microbiol Rev; 1996 Oct; 9(4):512-31. PubMed ID: 8894350 [TBL] [Abstract][Full Text] [Related]
2. Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles. Brajtburg J; Elberg S; Travis SJ; Kobayashi GS Antimicrob Agents Chemother; 1994 Feb; 38(2):294-9. PubMed ID: 8192455 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS). Fukui H; Koike T; Saheki A; Sonoke S; Tomii Y; Seki J Int J Pharm; 2003 Sep; 263(1-2):51-60. PubMed ID: 12954180 [TBL] [Abstract][Full Text] [Related]
4. In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system. Tabosa Do Egito ES; Appel M; Fessi H; Barratt G; Puisieux F; Devissaguet JP J Antimicrob Chemother; 1996 Sep; 38(3):485-97. PubMed ID: 8889723 [TBL] [Abstract][Full Text] [Related]
5. A novel heparin-coated hydrophilic preparation of amphotericin B hydrosomes. Clemons KV; Ranney DF; Stevens DA Curr Opin Investig Drugs; 2001 Apr; 2(4):480-7. PubMed ID: 11566003 [TBL] [Abstract][Full Text] [Related]
6. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS), with commercial lipid-based formulations. Fukui H; Koike T; Nakagawa T; Saheki A; Sonoke S; Tomii Y; Seki J Int J Pharm; 2003 Nov; 267(1-2):101-12. PubMed ID: 14602388 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of in vitro and in vivo Efficacy of a Novel Amphotericin B-Loaded Nanostructured Lipid Carrier in the Treatment of Rebouças-Silva J; Tadini MC; Devequi-Nunes D; Mansur AL; S Silveira-Mattos P; I de Oliveira C; R Formiga F; Berretta AA; Marquele-Oliveira F; Borges VM Int J Nanomedicine; 2020; 15():8659-8672. PubMed ID: 33177824 [TBL] [Abstract][Full Text] [Related]
8. Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index. Zia Q; Azhar A; Kamal MA; Aliev G; Owais M; Ashraf GM Curr Pharm Des; 2016; 22(7):792-803. PubMed ID: 26648472 [TBL] [Abstract][Full Text] [Related]
9. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection. Kaur K; Kumar P; Kush P Biomed Pharmacother; 2020 Aug; 128():110297. PubMed ID: 32480227 [TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility, stability and safety of an amphotericin B inhalation formulation. Gangadhar KN; Adhikari K; Srichana T Int J Pharm; 2014 Aug; 471(1-2):430-8. PubMed ID: 24907597 [TBL] [Abstract][Full Text] [Related]
11. In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid. Joly V; Farinotti R; Saint-Julien L; Chéron M; Carbon C; Yeni P Antimicrob Agents Chemother; 1994 Feb; 38(2):177-83. PubMed ID: 8192439 [TBL] [Abstract][Full Text] [Related]
12. Biodistribution and histopathology studies of amphotericin B sodium deoxycholate sulfate formulation following intratracheal instillation in rat models. Usman F; Nopparat J; Javed I; Srichana T Drug Deliv Transl Res; 2020 Feb; 10(1):59-69. PubMed ID: 31368043 [TBL] [Abstract][Full Text] [Related]
13. Amphotericin-B colloidal dispersion. A review of its use against systemic fungal infections and visceral leishmaniasis. Brogden RN; Goa KL; Coukell AJ Drugs; 1998 Sep; 56(3):365-83. PubMed ID: 9777313 [TBL] [Abstract][Full Text] [Related]
14. Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses. Brajtburg J; Elberg S; Kobayashi GS; Bolard J Antimicrob Agents Chemother; 1994 Feb; 38(2):300-6. PubMed ID: 8192456 [TBL] [Abstract][Full Text] [Related]
15. In-vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B obtained by mild heating. Petit C; Chéron M; Joly V; Rodrigues JM; Bolard J; Gaboriau F J Antimicrob Chemother; 1998 Dec; 42(6):779-85. PubMed ID: 10052902 [TBL] [Abstract][Full Text] [Related]
16. Amphotericin B lipid complex therapy of experimental fungal infections in mice. Clark JM; Whitney RR; Olsen SJ; George RJ; Swerdel MR; Kunselman L; Bonner DP Antimicrob Agents Chemother; 1991 Apr; 35(4):615-21. PubMed ID: 2069367 [TBL] [Abstract][Full Text] [Related]
17. Amphotericin B Loaded Nanostructured Lipid Carriers for Parenteral Delivery: Characterization, Antifungal and In vitro Toxicity Assessment. Nimtrakul P; Tiyaboonchai W; Lamlertthon S Curr Drug Deliv; 2019; 16(7):645-653. PubMed ID: 31362675 [TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
19. Bioactivity, Safety, and Efficacy of Amphotericin B Nanomicellar Aerosols Using Sodium Deoxycholate Sulfate as the Lipid Carrier. Usman F; Khalil R; Ul-Haq Z; Nakpheng T; Srichana T AAPS PharmSciTech; 2018 Jul; 19(5):2077-2086. PubMed ID: 29691753 [TBL] [Abstract][Full Text] [Related]
20. Lipid formulation as a drug carrier for drug delivery. Tomii Y Curr Pharm Des; 2002; 8(6):467-74. PubMed ID: 12069383 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]